TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Drugs Made In America Acquisition Corp. ( (DMAA) ) is now available.
On October 8, 2025, Glenn Worman resigned as Chief Financial Officer of Drugs Made In America Acquisition Corp., effective immediately, citing no disagreements with the company. On November 17, 2025, Saleem Elmasri was appointed as the new CFO, with his services provided through a consulting agreement with Titan Advisory Services LLC. Mr. Elmasri brings 20 years of financial and management consulting experience, having previously worked with PwC and other advisory firms, and is expected to enhance the company’s financial operations.
More about Drugs Made In America Acquisition Corp.
Average Trading Volume: 39,966
Technical Sentiment Signal: Strong Buy
See more insights into DMAA stock on TipRanks’ Stock Analysis page.